Details for Patent: 12,533,358
Which drugs does patent 12,533,358 protect, and when does it expire?
Patent 12,533,358 protects LYNKUET and is included in one NDA.
Summary for Patent: 12,533,358
| Title: | Methods of treatment with elinzanetant |
| Abstract: | The present disclosure relates to methods of treating vasomotor symptoms in a female subject in need thereof by administering a therapeutically effective amount of elinzanetant or a pharmaceutically acceptable salt or deuterated thereof, wherein the female subject is concurrently administered with a moderate CYP3A4 inhibitor. |
| Inventor(s): | Michael Block, Stefan Willmann, Alexander Solms, Annika Ruth Patricia Schneider, Marcus-Hillert SCHULTZE-MOSGAU |
| Assignee: | Bayer Consumer Care AG , Emerald Lake Safety LLC |
| Application Number: | US19/208,416 |
|
Patent Claim Types: see list of patent claims | Use; |
Drugs Protected by US Patent 12,533,358
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bayer Hlthcare | LYNKUET | elinzanetant | CAPSULE;ORAL | 219469-001 | Oct 24, 2025 | RX | Yes | Yes | 12,533,358 | ⤷ Start Trial | TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS DUE TO MENOPAUSE BY ADMINISTERING 60 MG (ONE CAPSULE) OF LYNKUET ORALLY ONCE DAILY AT BEDTIME CONCOMITANTLY WITH A MODERATE CYP3A4 INHIBITOR | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
